Skip to main content
BioInfra Life Science Inc. logo

BioInfra Life Science Inc. — Investor Relations & Filings

Ticker · 266470 ISIN · KR7266470004 KO Professional, scientific and technical activities
Open in API
Filings indexed 121 across all filing types
Latest filing 2022-02-04 Director's Dealing
Country KR South Korea
Listing KO 266470

About BioInfra Life Science Inc.

http://bioinfra.co.kr/?lang=en

BioInfra Life Science Inc. is a biotechnology company focused on cancer prevention, early detection, and treatment. The company's core technology is a multi-biomarker blood test, an in-vitro diagnostic solution designed for the early screening of eight major cancers, including lung, liver, stomach, colorectal, prostate, breast, pancreatic, and ovarian cancer. This test analyzes cancer risk from a small blood sample. In addition to its diagnostic platform, the company develops cancer gene treatments and technologies to monitor the potential for metastasis and recurrence, aiming to provide innovative solutions in the healthcare field.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is specifically used to report insider share transactions or changes in ownership by company directors and executives. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2022-02-04 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure period for an upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or proxy statements, but rather serves as a formal regulatory notice of the meeting preparation. Given the nature of the announcement as a regulatory disclosure, it fits best under the RNS category.
2021-12-16 Korean
기업설명회(IR)개최결과
Report Publication Announcement Classification · 100% confidence The document is a short, structured announcement reporting the results of an Investor Relations (IR) event held by Bioinfra Life Science. It provides details such as the date, location, attendees, and a summary of the topics covered (company status, technology, Q&A). Since it is a brief notification of an event that has already occurred rather than a full presentation deck or a comprehensive financial report, it falls under the category of a regulatory announcement regarding corporate activities.
2021-12-06 Korean
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a '정정신고(보고)' (Correction Report) for a previously submitted '사업보고서' (Annual Report/Business Report). It explicitly lists the original submission date (2021-03-23) and provides detailed corrections to the 'Business Content' section, specifically regarding research and development activities. In the Korean regulatory context (DART), a '사업보고서' is the equivalent of an Annual Report (10-K). Since this document is a formal amendment to that annual report, it is classified as an Annual Report (10-K). FY 2020
2021-10-27 Korean
기업설명회(IR)개최결과
Regulatory Filings Classification · 100% confidence The document is a short notification (under 1,000 characters) announcing the results of an Investor Relations (IR) event held on 2021-10-14. It provides details on the date, location, and participants, and mentions that the presentation materials are available on the Korea IR Council website. Per the 'Menu vs Meal' rule, since this is a brief announcement of an event and the availability of materials rather than the presentation itself, it is classified as a Report Publication Announcement (RPA).
2021-10-14 Korean
[기재정정]사업보고서 (2020.12)
Regulatory Filings Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서), which is the Korean equivalent of an Annual Report (10-K). It details specific corrections to non-financial and financial sections (research and development, personnel, etc.) of the original 2021 annual report. Since it is a formal regulatory filing correcting a comprehensive annual report, it falls under the category of Regulatory Filings (RNS) as it is an amendment/correction document rather than the primary report itself. FY 2020
2021-08-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.